Disease-modifying therapies are associated with a slower rate of disability accumulation in patients with active secondary progressive multiple sclerosis (SPMS), Australian-led research shows. An international study led by researchers from the University of Melbourne’s Clinical Outcomes Research Unit (CORe), has shown that relapses in patients with SPMS represent a treatable target and are associated with ...
Relapses during SPMS are a treatable target to reduce disability progression
By Michael Woodhead
30 Jul 2020